Predictors and outcomes of recurrent disease after a negative second look laparotomy
✍ Scribed by Ali Ayhan; Murat Gultekin; Polat Dursun; Nasuh Utku Dogan; Guldeniz Aksan; Suleyman Guven; Kunter Yuce
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 79 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background and Objectives
To analyze the predictors and outcomes of recurrent disease in patients with epithelial ovarian carcinoma (EOC) after a negative second look laparotomy (SLL).
Methods
One hundred nine EOC patients with a negative SLL treated at Hacettepe Hospital were retrospectively analyzed.
Results
Of these patients, 70 (64.2%) had no evidence of disease during follow up while remaining 39 (35.8%) had recurrence. Majority of the recurrences (82.1%) were detected within the initial 2 years of the SLL procedure. Multivariate analysis revealed stage and grade of the disease to be the significant predictors for the recurrent disease (P < 0.01 and P = 0.025, respectively). A second analysis with respect to initial metastatic sites revealed omental metastatis was significantly associated with recurrent disease (P < 0.001). Survival of patients with a recurrent disease was significantly poorer and dropped abruptly once a recurrence is developed.
Conclusions
Patients with initial omental metastasis, advanced stage and high grade tumors have highest risk for developing recurrences after a (−) SLL. Most of the recurrences develop during the initial 2 years following the (−) SLL and survival drops to less than 2 years once a recurrence is found. J. Surg. Oncol. 2008;97:226–230. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Surgical reexploration was performed in 46 patients with epithelial nonmucinous ovarian adenocarcinoma requiring adjuvant chemotherapy whose initial therapy consisted of optimum debulking and surgical staging. All patients were placed on CAP (cisplatinum, Adriamycin, cyclophosphamide) c